Clinical trials have shown that Dengvaxia has an overall efficacy rate of about 60% in reducing symptomatic dengue. The efficacy varies by serotype and previous exposure to the virus. For example, the vaccine is more effective against DENV 3 and DENV 4 compared to DENV 1 and DENV 2. The efficacy is also higher in individuals who have had a prior dengue infection compared to those who are dengue-naive.
